ClinicalTrials.gg
RecruitingNCT07757880Updated Nov 10, 2026

Randomized Evaluation of Operating Room Extubation After Cardiac Surgery

An interventional study of OR extubation and ICU extubation in Cardiac Surgery, sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

Updated Nov 10, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

We are studying whether waking patients up and removing the breathing tube (also known as "extubation") in the operating room after cardiac surgery improves postoperative recovery without causing harm.

Read the detailed description

This is a pragmatic, randomized controlled trial comparing OR extubation versus ICU extubation among adults undergoing elective cardiac surgery.

02

Conditions studied

  • Cardiac Surgery

Keywords

  • Extubation
  • Cardiac surgery
  • Cardiac surgery recovery
03

In context

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.

Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 18+) scheduled for elective cardiac surgery requiring cardiopulmonary bypass
  • Low perioperative risk defined as STS Predicted Risk of Mortality (PROM) ≤ 3% based on the latest STS Adult Cardiac Surgery Database (ACSD) Risk Calculator
  • Deemed appropriate for OR extubation preoperatively by the attending cardiac surgeon
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Underlying pulmonary disease requiring use of home supplemental oxygen
  • Pre-capillary pulmonary hypertension (mPAP ≥ 25 mmHg or PVR > 2 Wood units) on most recent right heart catheterization for any patient for which there is suspicion for pulmonary hypertension at the time of preoperative evaluation
  • Preoperative right ventricular dysfunction greater than mild on most recent echocardiogram
  • ≥ 35
  • Obstructive sleep apnea with home CPAP or biPAP use or recommended use
  • Neuromuscular disease associated with respiratory muscle weakness including myasthenia gravis, Lambert-Eaton myasthenic syndrome, or muscular dystrophy
  • Airway abnormalities including tracheostomy, history of difficult mask ventilation, history of difficult intubation requiring fiberoptic rescue or multiple (>2) attempts, known anatomic abnormalities including limited mouth opening (\< 3cm), severe micrognathia, tracheal stenosis, or tracheal compression due to mass or goiter

We will also exclude patients undergoing the following procedures:

  • Transplant surgery
  • Pulmonary thromboendarterectomy
  • Implantation of mechanical circulatory support including LVAD, Impella, intra-aortic balloon pump, RVAD, or ECMO
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    OR extubation

    Extubation in the operating room (OR) at the conclusion of cardiac surgery

    Procedure: OR extubation

  • Placebo comparator
    ICU extubation

    Extubation in the intensive care unit (ICU) within 6 hours of leaving the OR

    Procedure: ICU extubation

Interventions

  • ProcedureOR extubation

    Immediate extubation in the operating room (OR) at the conclusion of cardiac surgery

  • ProcedureICU extubation

    Extubation in the intensive care unit (ICU) within 6 hours of leaving the operating room after cardiac surgery

06

What researchers measure

Primary outcomes

  1. Hierarchical composite endpoint, ordered by clinical priority

    1. Death by postoperative day 15; 2. Unplanned reintubation or cumulative mechanical ventilation \> 12 hours from OR exit, assessed through 48 hours postoperatively; 3. Days at home through postoperative day 15 (DAH-15). DAH-15 will be measured from the time of post-operative ICU admission and will subtract any time spent in a hospital (index hospitalization or readmission), rehabilitation center, or nursing facility.

    Time frame: 15 days postoperatively

Secondary outcomes

  1. Postoperative ICU length of stay

    Cumulative length of stay (hours) in an intensive care unit (ICU) following cardiac surgery

    Time frame: 30 days

  2. Postoperative hospital length of stay

    Length of index hospitalization (hours) following cardiac surgery

    Time frame: 30 days

  3. Use of non-invasive respiratory support

    Use of non-invasive respiratory support such as biPAP, CPAP, or high flow oxygen after OR exit

    Time frame: 48 hours

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 10, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Feb 2027 → May 2027, last on Nov 10, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jun 2027, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 11, 2026
StartEst.
Nov 9, 2026was Aug 2026
Primary completionEst.
May 2027was Feb 2027
CompletionEst.
Jun 2027was Mar 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Massachusetts General Hospital · Boston, United Statesno status→Recruiting
  • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
Nov 10, 2026
Start date
Aug 2026→Nov 9, 2026
moved 2 times, Sep 28, 2026 – Nov 10, 2026
Primary completion
Feb 2027→May 2027
moved 2 times, Sep 28, 2026 – Nov 10, 2026
Study completion
Mar 2027→Jun 2027
Sep 28, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedBMI ≥ 35
Sep 28, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Brigham and Women's Hospital · Boston, United StatesContact •••2627→•••8210
  • Massachusetts General Hospital · Boston, United StatesContact added l•••@mgh.harvard.edu
across 2 updates, Sep 28, 2026 – Oct 29, 2026
Show all 3 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Massachusetts General Hospital · Boston, United Statesno status→Recruiting
    • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
    Start date Oct 2026→Nov 9, 2026
    Primary completion Apr 2027→May 2027
  2. Oct 29, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Brigham and Women's Hospital · Boston, United StatesContact •••2627→•••8210
    + 1 other change: verification date
  3. Sep 28, 2026
    Start date Aug 2026→Oct 2026
    Primary completion Feb 2027→Apr 2027
    Study completion Mar 2027→Jun 2027
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedBMI ≥ 35
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Brigham and Women's Hospital · Boston, United StatesContact •••2892→•••2627Contact l•••@mgb.org→c•••@bwh.harvard.eduContact added m•••@mgb.org
    • Massachusetts General Hospital · Boston, United StatesContact added l•••@mgh.harvard.edu
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07757880
Responsible party
Lauren E Gibson (Cardiac anesthesiologist, Massachusetts General Hospital) — Principal investigator
First posted
Aug 11, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Lauren Gibson, MD
Contact
legibson@mgh.harvard.edu
617-726-3030
Jordan Bloom, MD, MPH
Contact
jpbloom@mgh.harvard.edu
617-643-6058

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion